294 related articles for article (PubMed ID: 32971129)
1. p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort.
Schoop I; Maleki SS; Behrens HM; Krüger S; Haag J; Röcken C
Hum Pathol; 2020 Nov; 105():53-66. PubMed ID: 32971129
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
[TBL] [Abstract][Full Text] [Related]
3. Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist.
Tsuruta S; Ohishi Y; Fujiwara M; Ihara E; Ogawa Y; Oki E; Nakamura M; Oda Y
Hum Pathol; 2019 Jun; 88():27-38. PubMed ID: 30946937
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma.
Gonzalez RS; Messing S; Tu X; McMahon LA; Whitney-Miller CL
Hum Pathol; 2016 Oct; 56():16-21. PubMed ID: 27342907
[TBL] [Abstract][Full Text] [Related]
5. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract][Full Text] [Related]
7. Lineage analysis of early and advanced tubular adenocarcinomas of the stomach: continuous or discontinuous?
Nakayama T; Ling ZQ; Mukaisho K; Hattori T; Sugihara H
BMC Cancer; 2010 Jun; 10():311. PubMed ID: 20565940
[TBL] [Abstract][Full Text] [Related]
8. A case of gastric cancer with heterogeneous components of EB virus (+)/TP53 (+) and EB virus (-)/TP53 (-).
Matsuda I; Kan K; Doi S; Motoki Y; Onodera M; Hirota S
Int J Clin Exp Pathol; 2015; 8(9):11766-71. PubMed ID: 26617924
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations.
Wu MS; Shun CT; Wu CC; Hsu TY; Lin MT; Chang MC; Wang HP; Lin JT
Gastroenterology; 2000 Jun; 118(6):1031-8. PubMed ID: 10833477
[TBL] [Abstract][Full Text] [Related]
11. Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia.
Kohno Y; Yamamoto H; Hirahashi M; Kumagae Y; Nakamura M; Oki E; Oda Y
Hum Pathol; 2016 Jun; 52():145-52. PubMed ID: 26980051
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of sessile serrated adenoma/polyps with dysplasia/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study.
Murakami T; Akazawa Y; Yatagai N; Hiromoto T; Sasahara N; Saito T; Sakamoto N; Nagahara A; Yao T
Diagn Pathol; 2018 Nov; 13(1):88. PubMed ID: 30458818
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and molecular stability and methylation analyses of gastric papillary adenocarcinoma.
Uesugi N; Sugai T; Sugimoto R; Eizuka M; Fujita Y; Sato A; Osakabe M; Ishida K; Koeda K; Sasaki A; Matsumoto T
Pathology; 2017 Oct; 49(6):596-603. PubMed ID: 28830689
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma.
Setia N; Ahn S; Han HS; Park DY; Lauwers GY
Hum Pathol; 2019 Dec; 94():64-70. PubMed ID: 31676362
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort.
Röcken C; Behrens HM; Böger C; Krüger S
J Clin Pathol; 2016 Jan; 69(1):70-5. PubMed ID: 26251521
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression.
Huang SC; Ng KF; Yeh TS; Cheng CT; Chen MC; Chao YC; Chuang HC; Liu YJ; Chen TC
Histopathology; 2020 Aug; 77(2):250-261. PubMed ID: 32343857
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and molecular characteristics of gastric papillary adenocarcinoma.
Arai T; Komatsu A; Kanazawa N; Nonaka K; Ishiwata T
Pathol Int; 2023 Aug; 73(8):358-366. PubMed ID: 37341602
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma.
Issin G; Sayar İ; Demir F; Bakkaloğlu İG; Gamsizkan M; Yildiz Z; Yilmaz I; Özmen SA; Çağatay DV; Zemheri IE; Demiriz M; Günal A
J Environ Pathol Toxicol Oncol; 2023; 42(4):1-14. PubMed ID: 37522564
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and molecular alterations in early gastric cancers with the microsatellite instability-high phenotype.
Sugimoto R; Sugai T; Habano W; Endoh M; Eizuka M; Yamamoto E; Uesugi N; Ishida K; Kawasaki T; Matsumoto T; Suzuki H
Int J Cancer; 2016 Apr; 138(7):1689-97. PubMed ID: 26538087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
